Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Should We Screen Patients With HIV for NAFLD/NASH?

In this podcast episode, listen to hepatologist Giada Sebastiani, MD, discuss why the presence of obesity, metabolic syndrome, persistent elevation of ALT, or exposure to dideoxynucleoside analogues should trigger an evaluation for NAFLD and NASH, particularly in our aging population of patients with HIV.
Giada Sebastiani, MD
Released: November 10, 2021

In this episode, hepatologist Giada Sebastiani, MD, discusses why the presence of obesity, metabolic syndrome, persistent elevation of ALT, or exposure to dideoxynucleoside analogues can trigger an evaluation for NAFLD and NASH, particularly in our aging population of patients with HIV with topics including:

  • Metabolic factors  
  • HIV-related factors
  • Which patients with HIV are at risk

Information on this Educational Activity

Faculty

Giada Sebastiani, MD

Associate Professor of Medicine
McGill University Health Centre
Division of Gastroenterology and Hepatology and Division of Infectious Diseases
Clinician Scientist
Research Institute of McGill University Health Centre
Montreal, Quebec, Canada

Giada Sebastiani, MD, has disclosed that she has received funds for research support from Merck and Theratec; consulting fees from Allergan, Intercept, Gilead Sciences, Merck, Novartis, Novo Nordisk, and Pfizer; and fees for non-CME/CE services from AbbVie, Gilead Sciences, Merck, Novartis, Novo Nordisk, and Pfizer.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by
Theratechnologies Inc.

Related Content

Expert commentary on the role of incretins in management of glucose homeostasis and weight in patients with type 2 diabetes, from Clinical Care Options (CCO)

Carol Hatch Wysham, MD Released: October 5, 2022

Expert commentary on disease nomenclature based on underlying genetic factors, NASH heterogeneity, from Clinical Care Options (CCO)

Brent A. Neuschwander-Tetri, MD Released: September 29, 2022

Experts provide insight on best practices for management of type 2 diabetes and obesity including those in underserved populations. From Clinical Care Options (CCO)

Released: September 23, 2022

Unlocked downloadable slides featuring expert insight on the appropriate medical management of T2D and CKD from Clinical Care Options (CCO)

Vivian A. Fonseca, MD, FRCP Released: September 21, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings